NCT00537082

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 171 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	FTY720	Administered orally once daily for 6 months
DRUG	Placebo	Administered orally once daily for 6 months

Timeline

• Start date: 2007-09-01
• Primary completion: 2010-02-01
• First posted: 2007-09-28
• Last updated: 2011-04-21
• Results posted: 2011-03-23

Locations

18 sites across 1 country: Japan